Beyond Your Cancer

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients Treated

Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.

Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.

Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.

In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.

The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.

In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.

Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.

Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.

Investors

Review our SEC Filings, Codes of Conduct, & Management Teams.

Careers

We are always looking for talented people to join our team.

Our favorite prostate cancer support resources: 2018 edition

As the importance of patient involvement in determining their optimal post-treatment quality of life, these organizations educate and support the men and families affected by prostate cancer.

Dr. Moran, Improving Personalization and Confidence in Prostate Cancer Treatment

Dr. Brian J. Moran, Medical Director for the Chicago Prostate Cancer Center, stresses the importance of customizing each and every patient’s cancer treatment. “This disease is a spectrum disease,” says Moran.

Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates

“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.

Newsweek: “Prostate cancer is often diagnosed too late.”

Prostate cancer is one of the deadliest and most common cancers among men today. An article written by Melissa Matthews was recently published by Newsweek revealing that late detection plays a key role in why prostate cancer is so fatal.

Brachytherapy: An Innovative Disruptor

Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.

Join Us at the Following Events

AANS

American Association of Neurological Surgeons

April 30 - May 2, 2018 New Orleans, LA

AUA

American Urologic Association Annual Meeting 2018

May 18-22, 2018 San Francisco, CA

ABS

American Brachytherapy Society

2018 ABS Annual Meeting June 7-9, 2018 San Francisco, CA

Recent News

Brachytherapy: An Innovative Disruptor

Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.